It’s Not Too Late to Register for ACCP Updates in Therapeutics® 2019

Reserve your spot now for the ACCP Updates in Therapeutics® 2019 meeting at the St. Louis College of Pharmacy in St. Louis, Missouri, on April 27–28, 2019. Register now to take advantage of 2 full days of insights from nationally recognized faculty and a lineup of experts. The meeting will include educational programs tailored to support clinical pharmacists’ professional development needs and help those who are preparing for future Board of Pharmacy Specialties (BPS) specialty examinations in Pharmacotherapy and Critical Care Pharmacy.

Pharmacotherapy and Critical Care Pharmacy Review and Recertification Courses

ACCP courses are developed by experienced, board-certified specialists who are leaders in the field. Each course provides a comprehensive review of the knowledge domains covered in the respective specialty examination. Courses rely on a case-based approach, with emphasis on the reasoning required to address patient-specific drug-related problems in each therapeutic area. ACCP will present two courses in St. Louis: the Pharmacotherapy Preparatory Review and Recertification Course and the Critical Care Pharmacy Preparatory Review and Recertification Course. Both courses are BPS approved for recertification credit. Visit www.accp.com/ut to register.

Patient-Centered Team-Based Practice Forum

This 2-day forum is a one-of-a-kind learning opportunity for clinical pharmacists and trainees currently providing direct patient care in both primary care and specialty settings who are seeking to implement or enhance comprehensive medication management (CMM). The forum provides a firsthand opportunity to use the evidence-based tools and resources generated by the ACCP-funded CMM Effectiveness and Implementation Grant study. Sessions will employ workshop formats to help attendees create a customized CMM implementation plan tailored to their unique practice environment.

Visit www.accp.com/ut to register for the Patient-Centered Team-Based Practice Forum.

ACCP Academy Sessions

The ACCP Academy offers a flexible, curricular approach to enhancing participants’ skills and experience through three professional development programs: Leadership and Management, Research and Scholarship, and Teaching and Learning. Each curriculum includes required and elective programming delivered at ACCP’s live meetings. Sessions are interactive and provide participants with actionable concepts and skills they can immediately apply to their own professional pursuits. Visit www.accp.com/ut to register for ACCP Academy programming.

Location and Hotel Information

ACCP Updates in Therapeutics® 2019 will be held at the St. Louis College of Pharmacy in St. Louis, Missouri, in the Academic Research Building and the Recreation and Student Center. The buildings are conveniently located adjacent to each other and within steps of the campus Starbucks and Chick-fil-A. The campus dining hall is located inside the Recreation and Student Center and will be open for meeting attendees to purchase food and beverage. In addition, free parking will be available for all attendees. Several hotel options are available in the area surrounding the St. Louis College of Pharmacy. To see a list of conveniently located hotels, visit www.updatesintherapeutics.com/travel.aspx.

Space Is Limited for ACCP/ASHP Board Review and Recertification Courses

Enrollment in next month’s live ACCP/ASHP board review and recertification courses is filling up fast. Register now to reserve a spot. The three review and recertification courses to be offered live in in Minneapolis, Minnesota, on May 2–4, 2019, are Ambulatory Care Pharmacy, Geriatric Pharmacy, and Oncology Pharmacy. For more information and to register, visit www.rxcertifications.org/Live-Review-and-Recert-Courses.
Developed jointly by ACCP and ASHP and taught by leading experts, these comprehensive 3-day courses will use an interactive case-based instructional approach to present the domains, tasks, and knowledge statements developed by the Board of Pharmacy Specialties (BPS) for the relevant specialty examination. The registration fee for each board review course includes:

- Online audio recordings of the live course
- Printed course slide decks
- Online access to the course workbook in electronic (PDF) format
- Automatic (free) registration to the 2019 webinar “Developing Effective Test-Taking Skills” (to be presented in June 2019)
- The opportunity to earn continuing pharmacy education (CPE) credit for the course

Each course has been BPS approved for credit toward recertification in the relevant specialty: Ambulatory Care Pharmacy (BCACP), Geriatric Pharmacy (BCGP), or Oncology Pharmacy (BCOP). The registration fee for the recertification version of the courses includes:

- Online audio recordings of the live course
- Printed course slide decks
- Online access to the course workbook in electronic (PDF) format
- The opportunity to earn continuing pharmacy education (CPE) credit for the course
- Access to the online recertification posttest

Registration for each live course is open now at www.accp.com/meetings/ashpaccp18/index.aspx. Course enrollment size is limited; register now to secure a spot.

**Highlights from the CMM Effectiveness and Implementation Grant: A Report from the CMM Study Team**

Mary Roth McClurg, Pharm.D., MHS, FCCP

Data collection is complete across all aims of the ACCP-funded CMM Effectiveness and Implementation study. The study team continues to engage in data cleaning and data analysis for both the implementation and the effectiveness arms of the study; release study findings in the form of publications and presentations; and engage practitioners, organizations, payers, and health care providers in scaling CMM in primary care.

The study team is working closely with its AAFP and DARTNet colleagues, who are leading the data collection component of the study. The team has received electronic health record data from the study sites participating in this aim of the study, which are being formatted for analysis and for which the analytic code is being written. The analysis on clinical measures will be completed first, the results of which will then be incorporated into the cost-savings evaluation.

ACCP President Suzanne Nesbit’s March 2019 ACCP Report article titled “Implementing CMM to Achieve Medication Optimization” describes the importance of ACCP’s focused plans for disseminating and implementing the study’s findings. In partnership with ACCP, the study team is dedicated to identifying and pursuing strategies to educate practitioners, organizations, payers, and providers on learnings from the study that focus on opportunities to replicate and scale CMM.

Aside from the traditional academic dissemination of the study team’s learnings through publication in scientific/professional journals, a goal of the team has been to develop strategies for engaging practitioners in the tools and findings that have emerged from the study. One example of this type of strategy was the Patient-Centered Team-Based Practice Forum held during the 2018 ACCP Updates in Therapeutics® meeting. Similarly, the team will extend this work by participating in the practice forum at the 2019 ACCP Updates in Therapeutics® spring meeting in St. Louis to introduce and apply the principles and tools integral to CMM implementation and documentation. More information about the Patient-Centered Team-Based Practice Forum can be found in this issue of the ACCP Report and at www.updatesintherapeutics.com/practice_forum/index.aspx.

An additional strategy for engaging practitioners in an active and immersive experience will be through providing access to the study’s web-based, technology platform, Optimizing Medications for Better Health, which will contain the findings and tools produced from the study. This resource will enable users to access numerous educational materials, assessment tools, and a clinical documentation resource. The platform is expected to go live in July 2019 and will be accessible to all ACCP members. An early version of the platform will be used and showcased at the 2019 ACCP Updates in Therapeutics® spring meeting in St. Louis.

As in past communications, the study team continues to reflect on the importance of the partnership that has existed between the research team and the study sites over the past 3 years. This “implementation stream,” rich with many learnings and experiences, is truly unique and adds an entirely new dimension to the
previous research done around CMM or in pharmacy practice, in general. This study goes well beyond the traditional dissemination of data produced by a clinical practice through relying critically on the engagement of the “subjects” of the study – the frontline practitioners who took the time to test new ideas, participate in coaching calls and webinars, complete the many forms and surveys submitted to them, and share their experiences through interviews and focus groups. We, the study team, greatly appreciate the commitment, adaptability, and expertise of the 40+ clinical practitioners from the health care organizations who participated in this project.

**ACCP Student Chapter Annual Report Submissions and Award Applications Due June 30**

All ACCP student chapters are asked to submit their activities for the Annual Report of Student Chapter Activities to ACCP no later than June 30. Submission of this report is required to maintain status as an official ACCP chapter. This report provides updated information about ACCP chapter members, officers, and faculty/student liaisons and chapter activities, including membership drives, professional development projects, and participation in ACCP student competitions. Click here to access the current Annual Report of Student Chapter Activities.

**Student Chapter Awards**

ACCP offers two awards to recognize the outstanding contributions of student chapters and their members: the Outstanding Student Chapter Award and the Outstanding Student Chapter Member Award. Complete information about these awards is available in the ACCP Student Chapter Guide.

**Outstanding Student Chapter Award**

Chapters that wish to be considered for this award are asked to submit an essay detailing the chapter’s activities and achievements during the past academic calendar year, using the evaluation criteria listed in the essay form as a guide. Click here to access the Outstanding Student Chapter Award application.

**Outstanding Student Chapter Member Award**

Each chapter is responsible for selecting its own outstanding student chapter member and submitting his or her name to ACCP for recognition. ACCP has created an evaluation rubric for chapters to use in the selection process. Note: Each chapter’s Outstanding Student Member Award recipient will be listed on page 3 of the Annual Report.

Completed forms for the Outstanding Student Chapter and Outstanding Student Chapter Member awards must be submitted to membership@accp.com no later than Sunday, June 30. Please address any questions about the Annual Report of Student Chapter Activities or ACCP student chapter awards to Jon Poynter at jpoynter@accp.com.
ACCP is pleased to announce that competition is under way in the fourth annual Clinical Research Challenge (CRC). Research and scholarship contributes to improved health outcomes for patients and advances in the profession of clinical pharmacy. Critically evaluating and applying the primary literature is an essential skill for students pursuing a career in clinical pharmacy.

This innovative and unique competition offers teams of three students (those in the first 2 professional years of their degree program) an opportunity to compete and advance through three rounds of competition. The competition began February 11 with a record-setting 89 teams participating in round 1: The Online Journal Club. The Online Journal Club examination was based on the following literature:


Teams with the top 40 scores advanced to round 2: Letter of Intent (LOI) submission. These teams were given a clinically focused research question and had 2½ weeks to develop and submit a letter of intent following the criteria outlined here. The LOI submissions were evaluated by the CRC Review and Oversight panels. Teams who achieved the top 20 scores then advanced to round 3 and will submit a full research proposal that is based on their LOI submission and that incorporates the feedback from the reviewers. This year’s team proposal submissions, due April 19, will then be evaluated by the CRC Review and Oversight panels. Winners will be announced by June 8. To view a list of teams participating in each round of the competition, please click here.

About the ACCP Strategic Plan

Creating and updating the ACCP strategic plan involves considerable reflection, discussion, and teamwork. The College uses a continuous strategic planning cycle, including obtaining ongoing evaluations of its progress, using input from member surveys and focus groups, developing committees and task forces to address College initiatives and emerging issues, and publishing updates and revisions to the current strategic plan, as needed. In addition, the ACCP Board of Regents and staff regularly undertake a structured assessment and revision of the plan. Although ACCP’s core values and mission have remained steadfast over time, its vision and critical issues are periodically revisited to ensure that the organizational plan continues to evolve and be forward-thinking. The process requires a shared vision of organizational direction and the recognition that the individual missions of the College’s three interrelated corporate entities – ACCP, the ACCP Foundation, and Pharmacotherapy Publications, Inc. – all contribute to achieving that vision in unique ways.

The process for revising the current strategic plan began in February 2016, when the Board of Regents engaged in an environmental scan and assessed current and evolving organizational strengths, weaknesses, opportunities, and threats (SWOT). Targeted surveys were sent to samples of specific segments of the membership (new practitioners; PRN leaders; ACCP Fellows; and former ACCP, Pharmacotherapy, and ACCP Foundation board members) to gain their perspectives and identify additional emerging priority areas. More than 1000 members took part in this process, providing valuable feedback on proposed critical issues and ranking them in order of priority. About 100 members participated in the live focus groups held during the 2016 ACCP Annual Meeting. The board then collated and analyzed these member input data, and with additional refinement and editing, the final strategic plan was approved in July 2017.

The Board of Regents designed the plan’s objectives to be accomplished over 2–3 years. To successfully implement these initiatives, the College relies on the combined efforts of its members, whether by holding office, participating in committees, or serving as speakers, presenters, mentors, and recruiters. Soon, it will be time to update the 2017 strategic plan. The board will initiate the update in July and will again call on members to provide feedback and participate in this process. In addition, specific input can be submitted any time by visiting the ACCP feedback page at accp.com/feedback/index.aspx.

Washington Report
America’s Opioid Addiction: Optimizing Medications in a Public Health Crisis

John McGlew
Director of Government Affairs

America is in the grip of an addiction crisis – almost 64,000 Americans died of a drug overdose in 2016 alone, with opioid overdoses accounting for more
than 42,000 of these deaths – higher than during any previous year on record. In October 2017, President Donald Trump declared the opioid epidemic a public health emergency, and on Capitol Hill, a rare show of bipartisanship enabled passage of wide-ranging legislation that aims to prevent illicit fentanyl trafficking, account for drug diversion in opioid manufacturing quotas, and improve access to addiction treatments through telemedicine.

In recognition of this public health crisis, ACCP is working with a diverse range of stakeholders, including congressional leaders, federal task force structures, and other health professional societies, to ensure that medication optimization and effective management of all medications, including those prescribed for pain or addiction recovery, are central components of the policy initiatives aimed at addressing the crisis.

In 2018, ACCP released a statement to the Senate Finance Committee in response to a request for feedback on how to improve Medicare and Medicaid responses to the opioid epidemic. In this statement, ACCP specifically called for coverage for comprehensive medication management (CMM) to allow clinical pharmacists, as part of the patient care team, to identify appropriate goals for opioid therapy in individual patients, recommend alternatives if these goals are not met, and monitor adverse effects of opioids to mitigate the risks of oversedation and overdose. In addition, ACCP’s comments highlighted how clinical pharmacists providing CMM can assist in:

- Ensuring patients reach medication-related clinical goals that are established through shared decision-making with all members of the health care team.
- Addressing opioid use and/or misuse, when applicable.
- Educating patients and health care providers about acute and chronic pain therapeutics.
- Evaluating and implementing clinical pathways and systems to optimize the therapeutic use of opioids and other controlled substances.

American Society of Addiction Medicine

Consistent with its commitment to team-based care, the College is engaged in an ongoing dialogue with the American Society of Addiction Medicine (ASAM) to identify potential areas for collaboration and engagement.

ASAM is a professional medical society representing over 6000 physicians, clinicians, and associated professionals in the field of addiction medicine. ASAM is dedicated to increasing access to and improving the quality of addiction treatment, educating physicians and the public, supporting research and prevention, and promoting the appropriate role of physicians in the care of patients with addiction.

ACCP is currently exploring opportunities to develop the partnership with ASAM though providing collaborative educational sessions at ACCP and ASAM meetings, developing public policy statements, exploring clinical guidelines, and engaging in an advocacy partnership through the Coalition to Stop Opioid Overdose (CSOO), which ACCP formally joined in 2019.

Coalition to Stop Opioid Overdose

Founded in 2016, the Coalition to Stop Opioid Overdose (CSOO) brings together a diverse range of mental health, substance use disorder, and health care professional organizations united around common policy goals to reduce opioid overdose deaths. ACCP formally joined the coalition in 2019 to advance its policy platform, which includes:

- Changing the conversation about what it means to have a substance use disorder and challenging the stigma and discrimination associated with it.
- Strengthening the substance use disorder workforce.
- Removing barriers, and increasing equitable access, to evidence-based prevention, treatment, harm reduction, and recovery support services for all people with (or at risk of having) a substance use disorder who need these services, including evidence-based treatment for people who are incarcerated.
- Supporting research into effective prevention programs and pharmacologic and nonpharmacologic treatments for substance use disorder and chronic pain.

Dr. Corey Waller, chair of ASAM’s legislative advocacy committee, notes that “we are thrilled to have the American College of Clinical Pharmacy as a new member of the Coalition to Stop Opioid Overdose,” adding that:

Effective medication management is a critical component to reducing opioid-related overdose deaths. We look forward to working with ACCP to increase medication optimization and expand access to high-quality patient care for all who need it.

References:


The Comprehensive Addiction and Recovery Act (CARA) of 2016 is a landmark piece of legislation authorizing substantial federal funding to address the prescription opioid abuse and heroin use crisis, including the creation of the Pain Management Best Practices Inter-Agency Task Force (Task Force), whose mission is to determine whether gaps in or inconsistencies between best practices for acute and chronic pain management exist and to propose updates and recommendations to those practices.

The Task Force recently released a draft report describing the preliminary recommendations that will be finalized and submitted to Congress in 2019 after a 90-day public comment period. The preliminary report includes a call for input and comment from stakeholders on responses to some of the initial key concepts:

- Balanced pain management should be based on a biopsychosocial model of care.
- Individualized, patient-centered care is vital to addressing the public health pain crisis.
- Better and safer opioid stewardship must be ensured through risk assessments that are based on the patient’s medical, social, and family history to facilitate safe and appropriate prescribing.
- This will be a multidisciplinary approach to chronic pain that focuses on the patient’s medical condition, comorbidities, and various aspects of care including medications, restorative movement therapies, interventional procedures, complementary and integrative health, and behavioral health/psychological interventions.
- A multimodal approach to acute pain should be used in the surgical, injury, burn, and trauma settings.
- Perioperative surgical home and acute pain guidelines should be established to provide a framework for improved patient experience and outcomes.
- Drug shortages that may affect acute and chronic pain care should be addressed.
- Access to care is vital through improved health care coverage for various treatment modalities and an enlarged workforce of pain specialists and behavioral health clinicians to help guide and support appropriately trained primary care clinicians.
- Empathy and a nonjudgmental approach are important to improve treatment and outcomes, given that stigma is a major barrier to treatment.
- Education through societal awareness as well as provider education and training and patient education are needed to understand choices and promote therapeutic alliances between patients and providers.
- Research is required to develop a better understanding of the mechanisms of pain, preventive measures, use of innovative medical devices and medications to prevent the acute-to-chronic pain transition, and methods to improve outcomes of chronic pain conditions.
- Special populations should be highlighted, including children, women, older adults, American Indians/Alaskan Natives, and active-duty soldiers/veterans.

ACCP submitted comments in response to the call for input that stated the College’s belief that medication optimization is key to a comprehensive patient-centered approach to managing pain and other chronic or contributing medical comorbidities and that acute and chronic pain management requires an individualized, patient-centered approach.

More specifically, the comments included the following key recommendations:

- ACCP asserts that clinical pharmacists are essential team members in the multidisciplinary approach to chronic pain that focuses on the patient’s medical condition, comorbidities, and medication management services, including medication-assisted treatment (MAT) services for those with a dual diagnosis of chronic pain and opioid use disorder.
- ACCP recommends including pharmacy postgraduate programs in addition to graduate medical residency positions in pain specialties. Currently, there are only 25 accredited residency programs in pain management and palliative care pharmacy practice.
- ACCP supports improved access to care through an enlarged workforce of pain specialists and behavioral health clinicians to help guide and support appropriately trained primary care clinicians, with clinical pharmacists providing CMM services in primary care practices. ACCP also supports educational efforts, including provider education and training, and promoting therapeutic alliances between patients and providers, and recommends that pharmacy residencies be expanded and included in workforce considerations.
- ACCP supports innovative solutions to pain management such as telemedicine as part of the overall approach to pain management. ACCP
encourages further incorporation of pharmacists into innovative practices such as Project ECHO and the hub-and-spoke model that can increase the workforce’s ability to provide best-practice comprehensive and specialty care.

- ACCP recommends a comprehensive, team-based approach to managing chronic pain together with other medical comorbidities and a chronic disease management model that includes CMM services and aligns with value-based payment models.
- ACCP supports research of methods to improve the outcomes of chronic pain conditions.
- ACCP recommends the inclusion of research in practice advancement models across the disciplines in health care.

Click here to read ACCP’s comments in full.

Next Steps
Researchers at the Massachusetts General Hospital Institute for Technology Assessment estimate that restricting access to prescription opioids will only minimally affect the opioid overdose epidemic – a public health crisis that they project will only increase. ¹

In partnering with CSOO and ASAM, ACCP adds the voice and resources of clinical pharmacy to the voice and resources of those working to increase access to comprehensive, evidence-based outpatient treatment for Medicare beneficiaries with opioid use disorders; expand programs to treat substance use disorders, including MAT services; and expand grants for states and localities to improve their prescription drug-monitoring programs, collect public health data, implement other evidence-based prevention strategies, encourage data sharing between states, and support other prevention and research activities related to controlled substances, including education and awareness efforts.

References:

Pharmacotherapy’s Increasing International Impact

C. Lindsay DeVane, Pharm.D.
Editor-in-Chief, Pharmacotherapy

Pharmacotherapy’s publication history includes its increasing reach and international impact over the years. Briefly, Pharmacotherapy was founded by Russell R. Miller in 1980 as an independent journal dedicated to the publication of research and reviews in the area of pharmacotherapy. The initial years of publication were guided by an interdisciplinary editorial board of pharmacists and physicians who were recognized as authorities in various areas of drug therapy. Two of the 40 editorial board members in 1988 were from outside the United States. Today, 10 of the editorial board members are internationally based.

In 1988, when Pharmacotherapy became the first official journal of the American College of Clinical Pharmacy (ACCP), the paid circulation was less than 2000 copies per month. However, the journal’s exposure quickly increased as it became a hybrid publication of reviews and research reports together with official documents approved by the ACCP Board of Regents. Pharmacotherapy also published related articles documenting advances in clinical pharmacy. Last year, the paid circulation increased to greater than 17,000 with the continued growth of the College membership. An important milestone was achieved in 2018 when the Journal of the American College of Clinical Pharmacy (JACCP) was initiated, with Jerry Bauman, Pharm.D., as editor-in-chief. JACCP focuses on the spectrum of clinical pharmacy practice. This event is a demarcation for Pharmacotherapy to reemphasize its initial content of human pharmacology and drug therapy.

Given Pharmacotherapy’s mission to disseminate pharmacotherapeutic scholarship that improves human health, some statistics on the journal’s performance and reach may be useful to ACCP Report readers. Since 2012, when publication of the journal was transferred
to Wiley – one of the most prominent publishers of biomedical journals – access to the journal has increased remarkably. In 2018, over 6500 institutions worldwide had access to Pharmacotherapy through a publisher’s license or as part of consortia in multiple countries. In 2019, readership continues to grow by 10%–20% in many countries, including Egypt, India, and Japan and several European countries, to name a few. Not surprisingly, the increasing economic and social impact of China is mirrored by more than a 100% increase in the Chinese Pharmacotherapy readership since 2014.

Other metrics reflect increased use of the journal over time. The number of downloads of abstracts and full-text articles continues to increase. Pharmacotherapy averages over 40,000 unique visitors per month to its website, and full-text downloads are greater than 350,000 per year, with almost half from outside the United States.

The submission rate of new manuscripts also continues to climb, with over 700 manuscripts expected in 2019. This is an increase of over 30% from 2013. The level of interest in publishing in Pharmacotherapy requires the journal to be highly selective in its acceptance of manuscripts. The acceptance rate is currently 15%–20%. One benefit of an increased submission rate is the opportunity to publish articles that have greater impact on the field of pharmacotherapy and that are relevant to the journal’s readership. This outcome is reflected in the journal’s impact factor, which increased by 45% from 2.204 in 2013 to 3.196 in 2018.

Not only has the overall submission rate increased, but so has the submission of manuscripts from countries outside the United States. With the increasing availability of, and interest in, Pharmacotherapy, the authorship of submitted manuscripts is expected to reflect the worldwide research base in clinical pharmacology. In 2008, submissions to Pharmacotherapy originated from 33 countries outside the United States, representing 21% of new submissions. In 2013, this metric had risen to 31%. In 2018, 45% of new submissions originated from 45 countries outside the United States.

As the number of submissions to Pharmacotherapy has increased, so has the competition for space. Pharmacotherapy is not an insular journal. Preference is not given to U.S. or clinical pharmacist authors. The editors consider the scientific rigor and potential impact of submitted manuscripts to be the cardinal criteria in accepting manuscripts for publication. With the increasing number of manuscripts submitted from outside the United States, manuscripts are evaluated for global availability of the drugs being discussed and the potential impact of the pharmacotherapy issue being investigated. The editors of Pharmacotherapy recognize the increasing diversity of populations in nations around the world. This means that drug therapy issues once localized to one geographic region have become global issues. An example of the journal’s willingness to address global issues in pharmacotherapy is the recent publication of guidelines for optimizing use of the polymyxins in treating infectious disease (Pharmacotherapy 2019;39:10-39). This manuscript was developed by an international group of authorities and endorsed by international infectious disease/critical care organizations.

The editors of Pharmacotherapy believe that expanding the journal’s influence is both desirable and in the best interest for the drug therapy of all people, consistent with ACCP’s mission. The need to optimize drug therapy is an important global issue, and Pharmacotherapy’s reach and impact are rising to address this need.

ACCP National Resident Advisory Committee Applications Due June 14

Are you a resident or fellow who is interested in becoming more involved in ACCP? The American College of Clinical Pharmacy encourages postgraduate trainees who want to enhance their leadership skills, network with colleagues across the country, and interact with clinical pharmacy leaders to apply for appointment to the ACCCP National Resident Advisory Committee.

The National Resident Advisory Committee is a standing committee composed of residents, fellows, and graduate students appointed each year by the ACCP president-elect. Members serve a 1-year term, and the committee typically has 8–12 members. Appointed leadership positions include the chair (1-year term) and the vice chair (1-year term).

The committee serves in an advisory capacity to the ACCP Board of Regents and staff, providing feedback and assistance in developing new programs and services for resident members consistent with the College’s vision of clinical pharmacy practice, research, and education.

The committee will meet in person at the ACCP Global Conference in October and communicates by conference calls and e-mail to complete its assigned charges. Appointees to the National Resident Advisory Committee will receive a complimentary meeting registration to attend the ACCP Annual Meeting. For additional information on the application process or to enter your application, please visit www.accp.com/member-ship/rac.aspx. The deadline for applications is June 14, 2019.
2019 ACCP Clinical Pharmacy Challenge: Are You Ready?  
Online Team Registration Open – Local Competition Exam Available

ACCP’s novel pharmacy student team competition returns for its 10th season. The ACCP Clinical Pharmacy Challenge offers eligible teams the opportunity to compete in up to four online rounds, with the top eight teams advancing to the live quarterfinal competition at the 2019 ACCP Annual Meeting. Team registration is now available online. Plan now to participate this fall.

Competition Overview
The ACCP Clinical Pharmacy Challenge is a team-based competition in which teams of three students compete against teams from other schools and colleges of pharmacy in a “quiz bowl”-type format. Only one team per institution may enter the competition. Institutions with branch campuses, distance satellites, and/or several interested teams are encouraged to conduct a local competition. ACCP provides a local competition exam that institutions may use in selecting their team. Faculty members interested in using the exam may send an e-mail request to Michelle Kucera, Pharm.D., BCPS, at mkucera@accp.com.

Preliminary rounds of the 2019 national competition will be conducted virtually in August and September. The quarterfinal, semifinal, and final rounds will be held live at the 2019 ACCP Annual Meeting and 40th Anniversary Celebration in New York, New York, October 26–28, 2019.

Each round will consist of questions offered in the three distinct segments indicated below. Item content used in each segment will be developed and reviewed by an expert panel of clinical pharmacy practitioners and educators.

- Trivia/Lightning
- Clinical Case
- Jeopardy-style

Each team advancing to the quarterfinal round held at the 2019 ACCP Annual Meeting will receive three complimentary student full-meeting registrations. Each team member will receive an ACCP gift certificate for $125 and a certificate of recognition. In addition, semifinal teams not advancing to the final round will receive a semifinal team plaque for display at their institution. The second-place team will receive a $750 cash award ($250 to each member) and a commemorative team plaque. The winning team will receive a $1500 cash award ($500 to each member), and each team member will receive a commemorative plaque. A team trophy will be awarded to the winning institution.

Students are not required to be members of ACCP to participate. Team registration may be submitted online and must be initiated by a current faculty member at the respective institution. Students interested in forming a team should contact their ACCP faculty liaison. If no ACCP faculty liaison has been identified, any faculty member from the institution may initiate the registration process. The registering faculty member must confirm the eligibility of all team members and/or alternates online before a team will be permitted to compete in the Clinical Pharmacy Challenge. The deadline to complete team registration and confirm eligibility is September 3, 2019.

For more information on the ACCP Clinical Pharmacy Challenge, including the competition schedule, sample items, and FAQ section, please click here.
ACCP-PAC Contributions Support Bipartisan Health Care Leaders in Congress

Consistent with ACCP’s core values, ACCP-PAC supports candidates and elected officials who are committed to a care delivery system in which clinical pharmacists, as fully integrated members of the patient care team, are responsible for providing significant portions of medication management and helping achieve clinical goals for patients’ medication use.

As the 2020 presidential election approaches, ACCP-PAC has over $60,000 cash available to support elected officials and candidates running for federal office, thanks to the support of its members.

Although the partisan divide in Washington remains challenging, ACCP continues to build and develop relationships with true health care leaders from both parties who want to work with colleagues across the aisle to enact health care legislation focused on team-based, patient-centered care that measures and rewards quality and outcomes.

Clearly, the College’s message is resonating with policy-makers – medication optimization is increasingly recognized as a central component of the value-based approach to patient care. ACCP must also continue to support its friends on Capitol Hill to ensure that these leaders remain in Washington and continue to advance policies that meaningfully address the nation’s current health care issues.

ACCP-PAC is the only means through which the College can provide financial support for candidates for Congress. With its 17,000 members, ACCP is in a position to become one of the most prominent pharmacy PACs in Washington. To do this, the College needs the widespread support of its membership.

**CLICK HERE** to support your PAC today!

**Member Recruiters**

Many thanks to the following individuals for recruiting colleagues to join them as ACCP members:

Abby Bailey
Laura Carson
Allison Clemons
Shirley Felder
Daniel Ford
Katrina Gabriel
Olga Hilas
Kyoung-Sil Kang
Beatrix Lam
Lynn Lamkin
Joon Seok Lee

Katharine Madding
Daniel Majerczyk
Ramona McClain
Carly McKenzie
Lynda Nyamou
Lisa Peters
Meredith Sigler
James Stevenson
Kenyu Tan
Annelise Thomsen

---

**ACCP Updates in Therapeutics® 2019**

**REGISTER NOW!**

St. Louis, Missouri • St. Louis College of Pharmacy • April 27–28, 2019